Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for May 2, 2019 1:18 PM Agios Pharma (AGIO) Tops Q1 EPS by 16cMay 2, 2019 7:09 AM